19-Dec-2025
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
PRNewswire (Mon, 15-Dec 8:45 AM ET)
ANIX Advances Breast Cancer Vaccine After Phase 1 Data Shows 74% Immune Response Rate
Market Chameleon (Fri, 12-Dec 2:08 AM ET)
PRNewswire (Thu, 11-Dec 6:02 PM ET)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
PRNewswire (Wed, 10-Dec 9:00 AM ET)
PRNewswire (Mon, 17-Nov 8:15 AM ET)
Globe Newswire (Wed, 12-Nov 11:00 AM ET)
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
PRNewswire (Wed, 12-Nov 9:00 AM ET)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
PRNewswire (Mon, 10-Nov 10:30 AM ET)
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
PRNewswire (Wed, 5-Nov 8:55 AM ET)
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
PRNewswire (Thu, 23-Oct 8:47 AM ET)
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Anixa Biosciences trades on the NASDAQ stock market under the symbol ANIX.
As of December 19, 2025, ANIX stock price climbed to $3.30 with 399,084 million shares trading.
ANIX has a beta of 0.93, meaning it tends to be less sensitive to market movements. ANIX has a correlation of 0.07 to the broad based SPY ETF.
ANIX has a market cap of $108.63 million. This is considered a Micro Cap stock.
In the last 3 years, ANIX traded as high as $6.45 and as low as $2.07.
The top ETF exchange traded funds that ANIX belongs to (by Net Assets): VTI, VXF, IWC.
ANIX has outperformed the market in the last year with a return of +22.7%, while the SPY ETF gained +18.1%. However, in the most recent history, ANIX shares have underperformed the stock market with its stock returning 0.0% in the last 3 month period and -31.1% for the last 2 week period, while SPY has returned +2.8% and -0.5%, respectively.
ANIX support price is $3.04 and resistance is $3.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIX shares will trade within this expected range on the day.